Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

Relative bioavailability of three formulations of galunisertib administered as monotherapy in patients with advanced or metastatic cancer

Objective: Galunisertib (LY2157299 monohydrate), an inhibitor of the transforming growth factor β (TGFβ) pathway, is currently under investigation in several clinical trials involving multiple tumor types. The primary objective of this study was to assess relative bioavailability of two new galunise...

Full description

Bibliographic Details
Main Authors: Ivelina Gueorguieva, Ann Cleverly, Durisala Desaiah, Analia Azaro, Joan Seoane, Irene Braña, Elisabet Sicart, Colin Miles, Michael M Lahn, Malcolm I Mitchell, Jordi Rodon
Format: Article
Language:English
Published: BioExcel Publishing Ltd 2016-12-01
Series:Drugs in Context
Subjects:
LY2157299
transforming growth factor beta
area under curve
biological availability
half-life
pharmacokinetics
neoplasms
adverse drug event
Online Access:http://www.drugsincontext.com/relative-bioavailability-of-three-formulations-of-galunisertib-administered-as-monotherapy-in-patients-with-advanced-or-metastatic-cancer/

Internet

http://www.drugsincontext.com/relative-bioavailability-of-three-formulations-of-galunisertib-administered-as-monotherapy-in-patients-with-advanced-or-metastatic-cancer/

Similar Items